Clariant boosts US pharmaceutical production with Clear Lake expansion
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
The initial consideration for the transaction is US$ 12 million
SPARK has extended its influence to an additional 9.47 million students worldwide
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
Subscribe To Our Newsletter & Stay Updated